In fresh win for Shawver, Capstan’s in vivo CAR T platform draws Abbvie takeout

Abbvie’s purchase of Capstan for up to $2.1 billion represents a commitment to the biotech’s in vivo CAR T platform for immunological disorders, from which its lead program has only recently reached the clinic.

The agreement stands out among billion-dollar biotech M&A deals in recent years, as most biopharma buyers have targeted companies with late-stage or approved products. ...